What is the purpose of this trial?
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
Ages: 60 - 85 years
Janssen Research & Development, LLC
Dates: 09/25/2017 - 04/01/2023
Last Updated: 09/28/2017
Study HIC#: 1608018299